Thursday, July 25, 2019

FDA Approves BAQSIMI, The First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia

The U.S. Food and Drug Administration (FDA) has approved, Lilly’s BAQSIMI (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia… The post FDA Approves BAQSIMI, The First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia appeared first on ASweetLife.

from http://besthealthnews.com/2019/07/fda-approves-baqsimi-the-first-and-only-nasally-administered-glucagon-to-treat-severe-hypoglycemia/?utm_source=rss&utm_medium=rss&utm_campaign=fda-approves-baqsimi-the-first-and-only-nasally-administered-glucagon-to-treat-severe-hypoglycemia



from
https://healthnews010.tumblr.com/post/186555468188

No comments:

Post a Comment